Cargando…
JAK–STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma
Myxoid liposarcoma (MLS) shows extensive intratumoural heterogeneity with distinct subpopulations of tumour cells. Despite improved survival of MLS patients, existing therapies have shortcomings as they fail to target all tumour cells. The nature of chemotherapy‐resistant cells in MLS remains unknow...
Autores principales: | Dolatabadi, Soheila, Jonasson, Emma, Lindén, Malin, Fereydouni, Bentolhoda, Bäcksten, Karin, Nilsson, Malin, Martner, Anna, Forootan, Amin, Fagman, Henrik, Landberg, Göran, Åman, Pierre, Ståhlberg, Anders |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590236/ https://www.ncbi.nlm.nih.gov/pubmed/30650179 http://dx.doi.org/10.1002/ijc.32123 |
Ejemplares similares
-
FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma
por: Dolatabadi, Soheila, et al.
Publicado: (2022) -
Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo
por: Vannas, Christoffer, et al.
Publicado: (2022) -
Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses
por: Svec, David, et al.
Publicado: (2018) -
Normal and Functional TP53 in Genetically Stable Myxoid/Round Cell Liposarcoma
por: Ståhlberg, Anders, et al.
Publicado: (2014) -
HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo
por: Safavi, Setareh, et al.
Publicado: (2015)